Daniel Beck
Physician Assistant · Sikeston, MONPI 1992287544
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $87,795 of the $113,803 with a category attached, or 77.1%. Johnson & Johnson accounts for 97.7% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $41,215 and has fallen 53.4% since, to $19,212 in 2025. Among physician assistant clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 302 payments — averaging $376.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$111K
- Alkermes, Inc.$515
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$400
- Neurocrine Biosciences, Inc.$394
- Otsuka America Pharmaceutical, Inc.$216
- AbbVie$162
- plus $905 from 17 others
What the payments were for
- Consulting fees$3,7403%
- Speaking & faculty fees$87,79577%
- Travel & lodging$15,86714%
- Food & beverage$6,3486%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 189 | $111,210 |
| Alkermes, Inc. | 26 | $515 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $400 |
| Neurocrine Biosciences, Inc. | 19 | $394 |
| Otsuka America Pharmaceutical, Inc. | 13 | $216 |
| AbbVie | 9 | $162 |
| E.r. Squibb & Sons, L.L.C. | 2 | $154 |
| Teva Pharmaceuticals USA, Inc. | 3 | $144 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $118 |
| Lundbeck LLC | 6 | $101 |
| Avanir Pharmaceuticals, Inc. | 4 | $61 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| Merck | 3 | $40 |
| Novo Nordisk | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| Indivior Inc. | 2 | $28 |
| Lilly USA, LLC | 1 | $27 |
| OWP Pharmaceuticals, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$107,573
- INVEGA TRINZA$106,429
- INVEGA$1,020
- CAPLYTA$234
- SPRAVATO$228
- Austedo XR$124
- XIFAXAN$118
- INGREZZA$100
How this compares
$113,803 in reported general payments places this provider in the 95th percentile of 1,380 physician assistant providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 388 | $1,283,751 |
| Invega TrinzaPaliperidone Palmitate | 38 | $310,825 |
| IngrezzaValbenazine Tosylate | 52 | $260,572 |
| VraylarCariprazine Hcl | 159 | $137,001 |
| Memantine Hcl | 2,201 | $75,216 |
| Abilify MaintenaAripiprazole | 17 | $51,160 |
| RexultiBrexpiprazole | 59 | $49,438 |
| CaplytaLumateperone Tosylate | 18 | $38,935 |
| NamzaricMemantine Hcl/Donepezil Hcl | 126 | $38,589 |
| NuplazidPimavanserin Tartrate | 11 | $26,454 |
| Aripiprazole | 453 | $25,694 |
| NuedextaDextromethorphan Hbr/Quinidine | 33 | $23,154 |
| Quetiapine Fumarate | 860 | $13,045 |
| BelsomraSuvorexant | 47 | $12,523 |
| Memantine Hcl ErMemantine Hcl | 203 | $11,572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $111,210 | $1,594,576426 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $394 | $260,57252 claims |
| AbbVieVraylar, Namzaric | $162 | $175,590285 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $216 | $100,59776 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $400 | $38,93518 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $61 | $23,15433 claims |
| MerckBelsomra | $40 | $12,52347 claims |
| Lilly USA, LLCOlanzapine | $27 | $11,540477 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $33 | $6,79529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,380 physician assistant providers in Missouri.
Other physician assistant in Sikeston
- Jennifer DavissonKansas City$343K
- Andrew BergLees Summit$245K
- Sileen DowisKansas City$117K
- Amee RozancO Fallon$101K
- Autumn WillsCape Girardeau$37K
- Kimberly BrownSaint Louis$28K
- Marc ReitznerSpringfield$24K
- Justin AllphinOzark$23K
- Jacqueline CastagnoWentzville$19K
- Elizabeth BokermannBridgeton$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.